Download Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Indomethacin Injection Market: By Medical Use, By Distribution Channel, and Region Forecast 2021-2032
Indomethacin Injection Market: By Medical Use, By Distribution Channel, and Region Forecast 2021-2032
Report ID:37913
Published Date:Sep 2025
No of Pages:247
Format:
Indomethacin Injection Market size was valued at US$ 247.1 million in 2025 and is expected to reach US$ 412.6 million by 2032, growing at a significant CAGR of 7.6% from 2026-2032. For a long time, NSAIDs have been an essential treatment for the symptoms of osteoarthritis. NSAIDs exert anti-inflammatory and analgesic effects by allowing the prostaglandin-producing enzyme cyclooxygenase to enter the body (COX). Backache and different joint aches are routinely treated with non-steroidal anti-inflammatory medications (NSAIDs). Injections of indomethacin are NSAIDs. Indomethacin is also used to treat a congenital heart condition known as patent ductus arteriosus in neonates (PDA). Furthermore, the elderly are more likely to experience joint pain. Injections such as platelet-rich plasma and indomethacin are useful in reducing pain and inflammation. Furthermore, in the elderly population, these illnesses will significantly minimize the chance of infection in the affected joint. As a result of these reasons, the market is expected to rise in the future years.
Study Period
2026-2032Base Year
2025CAGR
7.6%Largest Market
EuropeFastest Growing Market
North-America
Swelling and pain and joint stiffness caused by arthritis, gout, bursitis, and tendonitis are treated with indomethacin. It is also used to treat several other ailments. A nonsteroidal anti-inflammatory drug is what this medication is called (NSAID). It works by preventing the formation of certain natural compounds that induce inflammation in your body. This impact aids in the reduction of edema and pain. These factors are driving the market. On the other hand, side effects of this injection are reduced urine output, lowered blood sugar, and weight gain, which restrained the market.
The market in North America is likely to hold the highest revenue share in 2022, and in the following years, it is predicted to increase rapidly. Restructuring the biopharmaceutical and pharmaceutical industries is driving the country's market expansion. Canada has seen substantial improvements in small-medium-sized biopharmaceutical, and pharmaceutical enterprises, as well as contract research organizations, as the tenth-largest market for pharmaceutical sales (CROs).
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2026-2032 |
|
Market CAGR |
7.6% |
|
By Medical Use |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
Indomethacin Injection Market size was valued at US$ 247.1 million in 2025 and is expected to reach US$ 412.6 million by 2032, growing at a significant CAGR of 7.6% from 2026-2032.
Hospira, Inc., Fresenius Kabi Aktiengesellschaft, Recordati S.P.A, APP Pharmaceuticals, Bedford Laboratories
North-America is the fastest-growing region for the market
Content Updated Date: Feb 2026
| 1.Executive Summary |
| 2.Global Indomethacin Injection Market Introduction |
| 2.1.Global Indomethacin Injection Market - Taxonomy |
| 2.2.Global Indomethacin Injection Market - Definitions |
| 2.2.1. Medical Use |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3.Global Indomethacin Injection Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Indomethacin Injection Market Analysis, 2021-2025 and Forecast 2026-2032 |
| 4.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Indomethacin Injection Market By Medical Use, 2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 5.1. Rheumatoid Arthritis |
| 5.1.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Ankylosing Spondylitis |
| 5.2.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Osteoarthritis |
| 5.3.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Gouty Arthritis |
| 5.4.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Acute painful shoulder bursitis or tendinitis |
| 5.5.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Headaches |
| 5.6.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Others |
| 5.7.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6.Global Indomethacin Injection Market By Distribution Channel, 2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 6.1. Hospital Pharmacies |
| 6.1.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Retail Pharmacies |
| 6.2.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Online Pharmacies |
| 6.3.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Indomethacin Injection Market By Region, 2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2021-2025 and Forecast 2026-2032, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Indomethacin Injection Market ,2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 8.1. Medical Use Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Rheumatoid Arthritis |
| 8.1.2.Ankylosing Spondylitis |
| 8.1.3.Osteoarthritis |
| 8.1.4.Gouty Arthritis |
| 8.1.5.Acute painful shoulder bursitis or tendinitis |
| 8.1.6.Headaches |
| 8.1.7.Others |
| 8.2. Distribution Channel Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacies |
| 8.2.2.Retail Pharmacies |
| 8.2.3.Online Pharmacies |
| 8.3. Country Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Indomethacin Injection Market ,2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 9.1. Medical Use Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Rheumatoid Arthritis |
| 9.1.2.Ankylosing Spondylitis |
| 9.1.3.Osteoarthritis |
| 9.1.4.Gouty Arthritis |
| 9.1.5.Acute painful shoulder bursitis or tendinitis |
| 9.1.6.Headaches |
| 9.1.7.Others |
| 9.2. Distribution Channel Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacies |
| 9.2.2.Retail Pharmacies |
| 9.2.3.Online Pharmacies |
| 9.3. Country Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Indomethacin Injection Market ,2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 10.1. Medical Use Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Rheumatoid Arthritis |
| 10.1.2.Ankylosing Spondylitis |
| 10.1.3.Osteoarthritis |
| 10.1.4.Gouty Arthritis |
| 10.1.5.Acute painful shoulder bursitis or tendinitis |
| 10.1.6.Headaches |
| 10.1.7.Others |
| 10.2. Distribution Channel Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacies |
| 10.2.2.Retail Pharmacies |
| 10.2.3.Online Pharmacies |
| 10.3. Country Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Indomethacin Injection Market ,2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 11.1. Medical Use Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Rheumatoid Arthritis |
| 11.1.2.Ankylosing Spondylitis |
| 11.1.3.Osteoarthritis |
| 11.1.4.Gouty Arthritis |
| 11.1.5.Acute painful shoulder bursitis or tendinitis |
| 11.1.6.Headaches |
| 11.1.7.Others |
| 11.2. Distribution Channel Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacies |
| 11.2.2.Retail Pharmacies |
| 11.2.3.Online Pharmacies |
| 11.3. Country Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Indomethacin Injection Market ,2021-2025 and Forecast 2026-2032 (Sales Value USD Million) |
| 12.1. Medical Use Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Rheumatoid Arthritis |
| 12.1.2.Ankylosing Spondylitis |
| 12.1.3.Osteoarthritis |
| 12.1.4.Gouty Arthritis |
| 12.1.5.Acute painful shoulder bursitis or tendinitis |
| 12.1.6.Headaches |
| 12.1.7.Others |
| 12.2. Distribution Channel Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacies |
| 12.2.2.Retail Pharmacies |
| 12.2.3.Online Pharmacies |
| 12.3. Country Analysis 2021-2025 and Forecast 2026-2032 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Zydus Pharmaceuticals, Inc |
| 13.2.2.Hospira, Inc. |
| 13.2.3.Fresenius Kabi Aktiengesellschaft |
| 13.2.4.Recordati S.P.A |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.